Emerging photothermal agents combined with immunotherapy for cancer treatment.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-10-21 DOI:10.1007/s12672-025-03669-8

Tian Xu, Xueping Yang, Xinyu Chen, Qilin Wang, Juncai Ye, Chuanyu You, Jiao Zhu, Yan Gui

{"title":"Emerging photothermal agents combined with immunotherapy for cancer treatment.","authors":"Tian Xu, Xueping Yang, Xinyu Chen, Qilin Wang, Juncai Ye, Chuanyu You, Jiao Zhu, Yan Gui","doi":"10.1007/s12672-025-03669-8","DOIUrl":null,"url":null,"abstract":"Background: Immunophotothermal therapy (IPTT), combining immune checkpoint inhibitors and photothermal therapy, represents a promising synergistic anticancer strategy that enhances tumour-specific immunity alongside localised thermal ablation.Aim: This review aims to summarise and critically analyse recent advancements in the development of photothermal agents for IPTT and their synergistic applications with immune checkpoint inhibitors.Methods: We focus specifically on the progress in innovative photothermal agent materials, the underlying mechanisms of immunophotothermal synergy, and the resulting antitumor efficacy evidenced by preclinical and clinical findings.Conclusions: Furthermore, the key challenges hindering clinical translation and potential future directions are discussed. This comprehensive analysis highlights the current state and prospects of IPTT as an effective multimodal cancer treatment paradigm.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1936"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540227/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03669-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Immunophotothermal therapy (IPTT), combining immune checkpoint inhibitors and photothermal therapy, represents a promising synergistic anticancer strategy that enhances tumour-specific immunity alongside localised thermal ablation.

Aim: This review aims to summarise and critically analyse recent advancements in the development of photothermal agents for IPTT and their synergistic applications with immune checkpoint inhibitors.

Methods: We focus specifically on the progress in innovative photothermal agent materials, the underlying mechanisms of immunophotothermal synergy, and the resulting antitumor efficacy evidenced by preclinical and clinical findings.

Conclusions: Furthermore, the key challenges hindering clinical translation and potential future directions are discussed. This comprehensive analysis highlights the current state and prospects of IPTT as an effective multimodal cancer treatment paradigm.

查看原文本刊更多论文

新兴光热剂联合免疫疗法治疗癌症。

背景：免疫光热疗法（IPTT），结合免疫检查点抑制剂和光热疗法，代表了一种有前途的协同抗癌策略，可以增强肿瘤特异性免疫和局部热消融。目的：本综述旨在总结和批判性分析用于IPTT的光热剂及其与免疫检查点抑制剂协同应用的最新进展。方法：重点介绍新型光热剂材料的研究进展，免疫光热协同作用的潜在机制，以及临床前和临床研究结果证明的抗肿瘤效果。结论：此外，讨论了阻碍临床翻译的主要挑战和潜在的未来方向。这一综合分析强调了IPTT作为一种有效的多模式癌症治疗范式的现状和前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊